Takeda Gets Chinese Regulatory Approval for Livtencity
By Ben Glickman
Livtencity, Takeda Pharmaceutical's treatment for cytomegalovirus, has received approval from Chinese regulators in certain cases.
The Japanese pharmaceutical company said Thursday that Livtencity, which goes by generic name maribavir, was approved by the National Medical Products Administration of China for treating adults with post-hematopoietic stem cell transplant or solid organ transplant cytomegalovirus infection or disease.
The approval specifically relates to cases that did not respond to other treatments.
The company secured breakthrough therapy designation by the China Center for Drug Evaluation in 2021.
Livtencity was originally approved in the U.S. for the treatment of cytomegalovirus infection and disease in 2021.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 21, 2023 16:27 ET (21:27 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks